Get in touch
Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.
NeoTYPE® MDS/CMML Profile
- Next Generation Sequencing (NGS)
This test is performed by sequencing the entire coding regions of the genes listed unless another method is noted. ASXL1, BCOR, BCORL1, BRAF, CALR, CBL, CEBPA, CUX1, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FLT3, GATA2, GNB1, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PDGFRA, PHF6, PIGA, PPM1D, PTEN, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAG2, STAT3, STAT5B, TET2, TP53, U2AF1, WT1, and ZRSR2.
Note: FLT3 by PCR (via FLT3 Mutation Analysis) is available to be ordered, as Client-Bill only, in conjunction with the NeoTYPE MDS/CMML Profile. It is reported separately from the NeoTYPE Profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.
Turnaround time
14 Days
Level of Service
- Global
New York Approved: Yes
Specimen Requirements
Bone marrow (Preferred): 2 mL in EDTA tube. Peripheral blood: 5 mL in EDTA tube. FFPE tissue: Paraffin block. Alternatively, send 1 H&E slide plus 10-14 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative is the recommended fixative. Do not use zinc or mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies. Note: Test in TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection. Please select Extract & Hold - TNA if specimen hold service is desired.
CPT Code(s)*
81450x1
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Last Updated: January 22, 2025